Literature DB >> 6234858

Cross-resistance among cinoxacin, ciprofloxacin, DJ-6783, enoxacin, nalidixic acid, norfloxacin, and oxolinic acid after in vitro selection of resistant populations.

A L Barry, R N Jones.   

Abstract

Six different gram-negative bacilli were serially transferred through subinhibitory concentrations of seven quinolone derivatives or related organic acids. A gradual, stepwise decrease in susceptibility was noted with all seven drugs, and the resistant cultures demonstrated a concomitant cross-resistance to the other drugs.

Entities:  

Mesh：

Substances：

Year:  1984        PMID： 6234858      PMCID： PMC185641          DOI： 10.1128/AAC.25.6.775

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN： 0066-4804            Impact factor:   5.191


  10 in total

1.  Cinoxacin: in vitro antibacterial studies of a new synthetic organic acid.

Authors:  R M Lumish; C W Norden
Journal:  Antimicrob Agents Chemother       Date:  1975-02       Impact factor: 5.191

2.  Pharmacokinetics and tissue penetration of ciprofloxacin.

Authors:  B Crump; R Wise; J Dent
Journal:  Antimicrob Agents Chemother       Date:  1983-11       Impact factor: 5.191

3.  A critical evaluation of nalidixic acid in urinary-tract infections.

Authors:  A R Ronald; M Turck; R G Petersdorf
Journal:  N Engl J Med       Date:  1966-11-17       Impact factor: 91.245

4.  Norfloxacin (MK-0366, AM-715): in vitro activity and cross-resistance with other organic acids including quality control limits for disk diffusion testing.

Authors:  R N Jones; A L Barry
Journal:  Diagn Microbiol Infect Dis       Date:  1983-06       Impact factor: 2.803

5.  Nalidixic acid resistance: a second genetic character involved in DNA gyrase activity.

Authors:  M Gellert; K Mizuuchi; M H O'Dea; T Itoh; J I Tomizawa
Journal:  Proc Natl Acad Sci U S A       Date:  1977-11       Impact factor: 11.205

6.  In vitro activity of ciprofloxacin (Bay o 9867).

Authors:  R J Fass
Journal:  Antimicrob Agents Chemother       Date:  1983-10       Impact factor: 5.191

7.  In vitro activity of enoxacin, a quinolone carboxylic acid, compared with those of norfloxacin, new beta-lactams, aminoglycosides, and trimethoprim.

Authors:  N X Chin; H C Neu
Journal:  Antimicrob Agents Chemother       Date:  1983-11       Impact factor: 5.191

8.  In vitro activity of Bay 09867, a new quinoline derivative, compared with those of other antimicrobial agents.

Authors:  R Wise; J M Andrews; L J Edwards
Journal:  Antimicrob Agents Chemother       Date:  1983-04       Impact factor: 5.191

9.  Rapid selection of organisms with increasing resistance on subinhibitory concentrations of norfloxacin in agar.

Authors:  J H Tenney; R W Maack; G R Chippendale
Journal:  Antimicrob Agents Chemother       Date:  1983-01       Impact factor: 5.191

10.  In vitro activity of norfloxacin, a quinolinecarboxylic acid, compared with that of beta-lactams, aminoglycosides, and trimethoprim.

Authors:  H C Neu; P Labthavikul
Journal:  Antimicrob Agents Chemother       Date:  1982-07       Impact factor: 5.191
  10 in total
  38 in total

Review 1.  Quinolone antimicrobial agents: adverse effects and bacterial resistance.

Authors:  J S Wolfson
Journal:  Eur J Clin Microbiol Infect Dis       Date:  1989-12       Impact factor: 3.267

Review 2.  The use of quinolones in developing countries.

Authors:  E Rodríguez-Noriega; R Morfin-Otero; S Esparza-Ahumada
Journal:  Drugs       Date:  1993       Impact factor: 9.546

3.  The fluoroquinolones: structures, mechanisms of action and resistance, and spectra of activity in vitro.

Authors:  J S Wolfson; D C Hooper
Journal:  Antimicrob Agents Chemother       Date:  1985-10       Impact factor: 5.191

4.  Clinical uses of nalidixic acid analogues: the fluoroquinolones.

Authors:  N Høiby
Journal:  Eur J Clin Microbiol       Date:  1986-04       Impact factor: 3.267

5.  Cross-resistance and cross-susceptibility between fluoroquinolone agents.

Authors:  A L Barry; P C Fuchs
Journal:  Eur J Clin Microbiol Infect Dis       Date:  1991-12       Impact factor: 3.267

6.  Studies on the emergence of resistance to lomefloxacin in vitro.

Authors:  M Kanematsu; D Greenwood
Journal:  Eur J Clin Microbiol Infect Dis       Date:  1989-08       Impact factor: 3.267

7.  Cloning and nucleotide sequence of Mycobacterium tuberculosis gyrA and gyrB genes and detection of quinolone resistance mutations.

Authors:  H E Takiff; L Salazar; C Guerrero; W Philipp; W M Huang; B Kreiswirth; S T Cole; W R Jacobs; A Telenti
Journal:  Antimicrob Agents Chemother       Date:  1994-04       Impact factor: 5.191

8.  Isolation and characterization of norfloxacin-resistant mutants of Escherichia coli K-12.

Authors:  K Hirai; H Aoyama; S Suzue; T Irikura; S Iyobe; S Mitsuhashi
Journal:  Antimicrob Agents Chemother       Date:  1986-08       Impact factor: 5.191

Review 9.  Pefloxacin. A review of its antibacterial activity, pharmacokinetic properties and therapeutic use.

Authors:  J P Gonzalez; J M Henwood
Journal:  Drugs       Date:  1989-05       Impact factor: 9.546

10.  Proposed interpretive criteria and quality control parameters for testing in vitro susceptibility of Neisseria gonorrhoeae to ciprofloxacin.

Authors:  P C Fuchs; A L Barry; C Baker; P R Murray; J A Washington
Journal:  J Clin Microbiol       Date:  1991-10       Impact factor: 5.948
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.